New tuberculosis vaccine is developed

Jun 06, 2007

U.S. scientists have announced development of a vaccine to prevent tuberculosis, one of the world's most deadly diseases.

Colorado State University researchers said their vaccine triggers the body's immunity in a novel way -- by activating specific immune system functions that enhance the response to the bacterium that causes tuberculosis.

Although still in preliminary stages of testing, scientists said the vaccine would likely be effective against all strains of TB, including multi-drug and extensively drug resistant tuberculosis. In addition, preliminary evidence shows the vaccine has promise of working after exposure to tuberculosis, which no other tuberculosis vaccine in current development has achieved.

"This novel vaccine system provides the template to design a series of new tuberculosis vaccines that could be very inexpensive to make," said Professor Ian Orme, head of the research team that developed the vaccine. "The next stage is to test the vaccine for long-lasting immunity and its ability to boost existing vaccines."

Human trials for the vaccine are expected within two to three years.

Copyright 2007 by United Press International

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Monkeys fear big cats less, eat more, with humans around

34 minutes ago

Some Monkeys in South Africa have been found to regard field scientists as human shields against predators and why not if the alternative is death by leopard? The researchers found the monkeys felt far safer ...

Report: China to declare Qualcomm a monopoly

2 hours ago

(AP)—Chinese regulators have concluded Qualcomm Inc., one of the biggest makers of chips used in mobile devices, has a monopoly, a government newspaper reported Friday.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments : 0